303 related articles for article (PubMed ID: 7489803)
1. Fibrinolytic and inflammatory processes in pleural effusions.
Philip-Joët F; Alessi MC; Philip-Joët C; Aillaud M; Barriere JR; Arnaud A; Juhan-Vague I
Eur Respir J; 1995 Aug; 8(8):1352-6. PubMed ID: 7489803
[TBL] [Abstract][Full Text] [Related]
2. Association between inflammatory mediators and the fibrinolysis system in infectious pleural effusions.
Alemán C; Alegre J; Monasterio J; Segura RM; Armadans L; Anglés A; Varela E; Ruiz E; Fernández de Sevilla T
Clin Sci (Lond); 2003 Nov; 105(5):601-7. PubMed ID: 12826021
[TBL] [Abstract][Full Text] [Related]
3. Fibrinolytic system in plasma and pleural fluid in malignant pleural mesothelioma.
Ozdemir O; Emri S; Karakoca Y; Sayinalp N; Akay H; Dündar S; Bariş I
Thromb Res; 1996 Oct; 84(2):121-8. PubMed ID: 8897701
[TBL] [Abstract][Full Text] [Related]
4. Blood fibrinolysis and the response to desmopressin in glomerulonephritis.
Brommer EJ; Van den Wall Bake AW; Dooijewaard G; van Loon BJ; Emeis JJ; Weening JJ
Thromb Haemost; 1994 Jan; 71(1):19-25. PubMed ID: 8165642
[TBL] [Abstract][Full Text] [Related]
5. Fibrinolytic system during long-distance running in IDDM patients and in healthy subjects.
van Loon BJ; Heere LP; Kluft C; Briët E; Dooijewaard G; Meinders AE
Diabetes Care; 1992 Aug; 15(8):991-6. PubMed ID: 1505332
[TBL] [Abstract][Full Text] [Related]
6. Progress of fibrinolysis during tumor necrosis factor infusions in humans. Concomitant increase in tissue-type plasminogen activator, plasminogen activator inhibitor type-1, and fibrin(ogen) degradation products.
van Hinsbergh VW; Bauer KA; Kooistra T; Kluft C; Dooijewaard G; Sherman ML; Nieuwenhuizen W
Blood; 1990 Dec; 76(11):2284-9. PubMed ID: 1701665
[TBL] [Abstract][Full Text] [Related]
7. Evidence for an active fibrinolytic system in normal human bone marrow.
McWilliam NA; Robbie LA; Barelle CJ; Adey G; Prasad S; Bennett B; Booth NA
Br J Haematol; 1996 Apr; 93(1):170-6. PubMed ID: 8611456
[TBL] [Abstract][Full Text] [Related]
8. Platelet hyperactivation in patients with essential thrombocythemia is not associated with vascular endothelial cell damage as judged by the level of plasma thrombomodulin, protein S, PAI-1, t-PA and vWF.
Bellucci S; Ignatova E; Jaillet N; Boffa MC
Thromb Haemost; 1993 Nov; 70(5):736-42. PubMed ID: 8128427
[TBL] [Abstract][Full Text] [Related]
9. Pathways of fibrin turnover of human pleural mesothelial cells in vitro.
Idell S; Zwieb C; Kumar A; Koenig KB; Johnson AR
Am J Respir Cell Mol Biol; 1992 Oct; 7(4):414-26. PubMed ID: 1389210
[TBL] [Abstract][Full Text] [Related]
10. Plasminogen activators and plasminogen activator inhibitors in blood and tumour fluids of patients with ovarian cancer.
Casslén B; Bossmar T; Lecander I; Astedt B
Eur J Cancer; 1994; 30A(9):1302-9. PubMed ID: 7999418
[TBL] [Abstract][Full Text] [Related]
11. Residual plasminogen activator inhibitor activity after venous stasis as a criterion for hypofibrinolysis: a study in 83 patients with confirmed deep vein thrombosis.
Nguyen G; Horellou MH; Kruithof EK; Conard J; Samama MM
Blood; 1988 Aug; 72(2):601-5. PubMed ID: 3135860
[TBL] [Abstract][Full Text] [Related]
12. Depression of tissue-type plasminogen activator and enhancement of urokinase-type plasminogen activator as an expression of local inflammation.
Brommer EJ; Dooijewaard G; Dijkmans BA; Breedveld FC
Thromb Haemost; 1992 Aug; 68(2):180-4. PubMed ID: 1412164
[TBL] [Abstract][Full Text] [Related]
13. Repeated thoracenteses affect proinflammatory cytokines, vascular endothelial growth factor, and fibrinolytic activity in pleural transudates.
Chung CL; Yeh CY; Sheu JR; Chen YC; Chang SC
Am J Med Sci; 2007 Dec; 334(6):452-7. PubMed ID: 18091367
[TBL] [Abstract][Full Text] [Related]
14. Analysis of intraarticular fibrinolytic pathways in patients with inflammatory and noninflammatory joint diseases.
Kummer JA; Abbink JJ; de Boer JP; Roem D; Nieuwenhuys EJ; Kamp AM; Swaak TJ; Hack CE
Arthritis Rheum; 1992 Aug; 35(8):884-93. PubMed ID: 1379429
[TBL] [Abstract][Full Text] [Related]
15. Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). Binding of t-PA/PAI-1 complexes to fibrin mediated by both the finger and the kringle-2 domain of t-PA.
Wagner OF; de Vries C; Hohmann C; Veerman H; Pannekoek H
J Clin Invest; 1989 Aug; 84(2):647-55. PubMed ID: 2503541
[TBL] [Abstract][Full Text] [Related]
16. Physical activity status and adverse age-related differences in coagulation and fibrinolytic factors in women.
DeSouza CA; Jones PP; Seals DR
Arterioscler Thromb Vasc Biol; 1998 Mar; 18(3):362-8. PubMed ID: 9514404
[TBL] [Abstract][Full Text] [Related]
17. Fibrinolytic activity in peripheral atherosclerosis in the elderly.
van der Bom JG; Bots ML; Haverkate F; Meyer P; Hofman A; Grobbee DE; Kluft C
Thromb Haemost; 1999 Feb; 81(2):275-80. PubMed ID: 10064006
[TBL] [Abstract][Full Text] [Related]
18. Analysis of fibrinolytic proteins in relation to DNA ploidy in prostate cancer.
Plas E; Carroll VA; Jilch R; Mihaly J; Vesely M; Ulrich W; Pflüger H; Binder BR
Int J Cancer; 1998 Oct; 78(3):320-5. PubMed ID: 9766566
[TBL] [Abstract][Full Text] [Related]
19. Abnormalities of pathways of fibrin turnover in the human pleural space.
Idell S; Girard W; Koenig KB; McLarty J; Fair DS
Am Rev Respir Dis; 1991 Jul; 144(1):187-94. PubMed ID: 2064128
[TBL] [Abstract][Full Text] [Related]
20. Fibrinolytic parameters in spermatozoas and seminal plasma.
Maier U; Kirchheimer JC; Hienert G; Christ G; Binder BR
J Urol; 1991 Sep; 146(3):906-8. PubMed ID: 1908531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
